183500-34-7

Usage

Uses

Used in Pharmaceutical Industry:
(1-TRITYL-1H-IMIDAZOL-4-YL)METHYL ACETATE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its trityl-protected imidazole structure allows for the development of new drugs with improved stability and efficacy.
Used in Materials Science:
(1-TRITYL-1H-IMIDAZOL-4-YL)METHYL ACETATE is used as a component in the fabrication of advanced materials, such as polymers and coatings, due to its unique chemical properties and reactivity.
Used in Organic Synthesis:
(1-TRITYL-1H-IMIDAZOL-4-YL)METHYL ACETATE is used as a protecting group in chemical reactions, allowing for selective reactions to occur on specific functional groups while protecting others from unwanted reactions. This enhances the efficiency and selectivity of organic synthesis processes.

Upstream product

• 33769-07-2 4-(hydroxymethyl)-1-(triphenylmethyl)imidazole 
• 76-83-5 trityl chloride 

Downstream Products

• 198648-98-5 [3-(4-cyanobenzyl)-3H-imidazol-4-yl]methyl acetate 
• 833490-36-1 [1-(4-methoxybenzyl)-1H-5-imidazolyl]methyl acetate 
• 854714-87-7 [1-(4-methylbenzyl)-1H-5-imidazolyl]methyl acetate 
• 833490-35-0 [1-(4-trifluoromethylbenzyl)-1H-5-imidazolyl]methyl acetate 
• 626242-04-4 (1-benzyl-1H-5-imidazolyl)methyl acetate 

Relevant academic research and scientific papers

Design and synthesis of piperidine farnesyltransferase inhibitors with reduced glucuronidation potential

The design and synthesis of a novel piperidine series of farnesyltransferase (FTase) inhibitors with reduced potential for metabolic glucuronidation are described. The various substitution and exchange of the phenyl group at the C-2 position of the previously described 2-(4-hydroxy)phenyl-3-nitropiperidine 1a (FTase IC50 = 5.4 nM) resulted in metabolically stable compounds with potent FTase inhibition (14a IC50 = 4.3 nM, 20a IC50 = 3.0 nM, and 50a IC50 = 16 nM). Molecular modeling studies of these compounds complexed with FTase and farnesyl pyrophosphate are also described.

Novel N-(4-piperidinyl)benzamide antimalarials with mammalian protein farnesyltransferase inhibitory activity

Protein farnesyltransferase of Plasmodium falciparum is a potential target in the treatment of malaria for which increased drug resistance is observed. The design, synthesis and evaluation of a series of N-(4-piperidinyl)benzamides is reported. The most potent compounds showed in vitro activity against the parasite at submicromolar concentrations.

Potent and selective farnesyl transferase inhibitors

We recently described a novel series of CA1A2X peptidomimetics as farnesyl transferase inhibitors (FTIs). These compounds possess an N-(4-piperidinyl)benzamide scaffold mimicking A1A 2 residue. Extensive exploration of structure-activity relationships revealed that replacement of cysteine by substituted benzylimidazoles provided nanomolar FTIs with in vitro activities (18e, IC50 = 4.60 nM on isolated enzyme, EC50 = 20.0 nM for growth inhibition on a tumor cell line). The molecular docking of 18e and 19e in the active site of the enzyme provided details of key interactions with the protein and showed that the methionine or phenylalanine residue fits into the aryl binding site.

Method of treating cancer

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

INHIBITORS OF PRENYL-PROTEIN TRANSFERASE

The present invention is directed to peptidomimetic piperazine-containing macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras

Inhibitors of prenyl-protein transferase

The present invention comprises piperazinone-containing compounds which inhibit prenyl-protein transferases, including famesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.

Inhibitors of prenyl-protein transferase

The present invention comprises piperazinone-containing compounds, which may be useful as inhibitors of prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.

Inhibitors of prenyl-protein transferase

The present invention is directed to macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invent

Inhibitors of prenyl-protein transferase

The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds

Inhibitors of prenyl-protein transferase

The present invention is directed to macrocyclic compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemothera-peutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.